Abstract
Background Semicarbazide-sensitive amine oxidase (SSAO) is an enzyme that performs oxidative deamination of primary amines to aldehyde, ammonia and hydrogen peroxide. It appears that these products may have important signalling function in the regulation of cell development and glucose homeostasis. Much attention has been given to raised plasma SSAO activity in diabetic patients, both types 1 and 2. We were interested whether the peroral antidiabetic drug metformin affects SSAO activity in vitro. In this study we used metformin because it is usually the first-line medication used for treatment of type 2 diabetes.
Highlights
Semicarbazide-sensitive amine oxidase (SSAO) is an enzyme that performs oxidative deamination of primary amines to aldehyde, ammonia and hydrogen peroxide
The highest concentration of SSAO was determined in the gastrointestinal system, especially in the liver (32 ± 4.0 mU/mg protein)
Our results indicated that metformin had no effect on SSAO activity in vitro
Summary
Semicarbazide-sensitive amine oxidase (SSAO) is an enzyme that performs oxidative deamination of primary amines to aldehyde, ammonia and hydrogen peroxide. It appears that these products may have important signalling function in the regulation of cell development and glucose homeostasis. Much attention has been given to raised plasma SSAO activity in diabetic patients, both types 1 and 2. We were interested whether the peroral antidiabetic drug metformin affects SSAO activity in vitro. In this study we used metformin because it is usually the first-line medication used for treatment of type 2 diabetes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
